Catalyst

Slingshot members are tracking this event:

Phase 3 STATUS Data Evaluating SAGE-547 for Super-Refractory Status Epilepticus (SRSE) Due H1 2017 - Originally expected 2nd Half of 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SAGE

100%

Additional Information

Additional Relevant Details SAGE announced updated guidance for the expected readout of top-line results for its STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus), a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating SAGE-547 as a treatment for patients with super-refractory status epilepticus (SRSE). SRSE is a rare, life-threatening condition of persistent seizure where treatment regimens normally sufficient in stopping seizure activity have failed, and for which there are no approved therapies. Top-line results for the Phase 3 clinical trial are now expected in the second half of 2016.
http://investor.sage...
Additional Relevant Details Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017
http://investor.sage...
Clinical Data Clinical Trial Information
https://clinicaltria...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 12, 2017
Occurred Source:
Related Keywords Phase 3 Data, Sage-547, Srse